A Study of INO-A002 in Healthy Dengue Virus-naive Adults

This is a Phase 1, open label, single center, dose escalation study to evaluate the safety,
tolerability and pharmacokinetic profile of dMAb-ZK190 following delivery of INO-A002 with
Hylenex® recombinant delivered IM followed by EP in healthy adult Dengue naïve volunteers
ages 18-60 years.

The study will apply a 3+3 design such that 3 additional subjects will be enrolled into the
cohort if one DLT (Section 7.3.1) is observed in one out of the first 3 subjects dosed during
the 28-day period of safety and PK assessment. If no additional DLT is observed in 3
additional subjects (i.e., 1 DLT in 6 total subjects), dosing will proceed to the subsequent
cohort. However, if any additional DLT occurs (i.e., >1 DLT in 6 total subjects), then that
dose will be deemed not tolerated and the prior dose will be considered the maximum tolerated
dose (MTD).

Inclusion Criteria:

1. Age 18-60 years;

2. Able to provide consent to participate and having signed an Informed Consent Form
(ICF);

3. Able and willing to comply with all study procedures;

4. Body mass index (BMI) between 20 and 30, inclusive

5. Screening laboratory must be within normal limits or have only Grade 0-1 findings;

6. Normal screening ECG or screening ECG with no clinically significant findings;

7. Women of child-bearing potential agree to use medically effective contraception (oral
contraception, barrier methods, spermicide, etc.) or have a partner who is sterile
from enrollment to 6 months following the last injection, or have a partner who is
medically unable to induce pregnancy.

8. Sexually active men who are considered sexually fertile must agree to use either a
barrier method of contraception during the study, and agree to continue the use for at
least 6 months following the last injection, or have a partner who is permanently
sterile or is medically unable to become pregnant;

9. No history of clinically significant immunosuppressive or autoimmune disease.
Individuals with HIV infection that have been virologically suppressed for more than 1
year and with current CD4 cell count entry greater than 500 cells/ul will be allowed
into the study.

10. No history of dengue virus vaccination or illness; no history of yellow fever
vaccination.

11. Dengue seronegative at baseline by screening laboratory evaluation

12. Not currently or within the previous 4 weeks taking immunosuppressive agents
(excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose
methotrexate, or prednisone at a dose less than 10 mg/day or steroid dose-equivalent).

Exclusion Criteria:

1. Administration of an investigational compound either currently or within 30 days of
first dose;

2. Previous receipt of an investigational product for the treatment or prevention of Zika
virus except if participant is verified to have received placebo;

3. Administration of any vaccine within 4 weeks of first dose;

4. Administration of any monoclonal or polyclonal antibody product within 4 weeks of the
first dose

5. Administration of any blood product within 3 months of first dose;

6. Pregnancy or breast feeding or plans to become pregnant during the course of the
study;

7. Positive serologic result for dengue virus (any serotype) or history of receipt of
either dengue virus or yellow fever virus vaccination at any time in the past;

8. Positive serologic test for hepatitis B surface antigen (HBsAg); or any potentially
communicable infectious disease as determined by the Principal Investigator or Medical
Monitor;

9. Positive serologic test for hepatitis C (exception: successful treatment with
confirmation of sustained virologic response);

10. Baseline evidence of kidney disease as measured by creatinine greater than 1.5 (CKD
Stage II or greater);

11. Baseline screening lab(s) with Grade 2 or higher abnormality, except for Grade 2
creatinine;

12. Chronic liver disease or cirrhosis;

13. Immunosuppressive illness including hematologic malignancy, history of solid organ or
bone marrow transplantation;

14. Current or anticipated concomitant immunosuppressive therapy (excluding inhaled,
topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or
prednisone at a dose greater than 10 mg/day or steroid dose-equivalent);

15. Current or anticipated treatment with TNF-α inhibitors such as infliximab, adalimumab,
etanercept;

16. Prior major surgery or any radiation therapy within 4 weeks of group assignment;

17. Any pre-excitation syndromes, e.g., Wolff-Parkinson-White syndrome;

18. Presence of a cardiac pacemaker or automatic implantable cardioverter defibrillator
(AICD)

19. Metal implants within 20 cm of the planned site(s) of injection;

20. Presence of keloid scar formation or hypertrophic scar as a clinically significant
medical condition at the planned site(s) of injection.

21. Prisoner or participants who are compulsorily detained (involuntary incarceration) for
treatment of either a physical or psychiatric illness;

22. Active drug or alcohol use or dependence that, in the opinion of the investigator,
would interfere with adherence to study requirements or assessment of immunologic
endpoints; or

23. Not willing to allow storage and future use of samples for Zika virus related research

24. Any illness or condition that in the opinion of the investigator may affect the safety
of the participant or the evaluation of any study endpoint.

25. Subjects who plan to travel within 6 months of INO-A002 administration to a geographic
location where DENV or ZIKV are currently active.

26. Subjects with known bleeding diatheses or that are using blood thinners for 30 days
before study enrollment including warfarin, heparin, Clopidogrel, Apixaban (Eliquis),
Dabigatran (Pradaxa), Edoxaban (Savaysa), Rivaroxaban (Xarelto). The use of low dose
aspirin (81 mg daily) will be acceptable.